Every GLP-1 drug that moved the obesity field came with a needle. Orforglipron breaks that pattern. It is the first small-molecule GLP-1 receptor agonist to reach FDA approval as a once-daily pill — no injection, no reconstitution, no cold chain. Eli Lilly markets it under the brand name Foundayo, and the FDA cleared it for chronic weight management on April 1, 2026.
The catch is in the numbers. Orforglipron activates a single receptor — GLP-1 — where the most powerful injectables engage two or three. In its pivotal obesity trial it reported roughly 12% weight loss, which is real and clinically meaningful, but below what the injectable dual and triple agonists tirzepatide and retatrutide have reported. Here is what orforglipron is, how the pill actually works, and where it lands against the injections.
Research-context information only. Orforglipron (brand name Foundayo) is FDA-approved as a prescription oral tablet for chronic weight management; any unapproved, compounded, or grey-market forms sold outside that channel are not FDA-approved and are sold for research purposes only. Data reported below comes from published clinical trials and regulatory filings. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What Orforglipron Is
Orforglipron, development code LY3502970, is an oral, once-daily, non-peptide small-molecule GLP-1 receptor agonist. It was originally discovered by Chugai and licensed to Eli Lilly in 2018. On April 1, 2026 the FDA approved it under the brand name Foundayo for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. A separate application for type 2 diabetes has been filed but is not approved as of this writing.
The phrase "small molecule" is the whole story. The injectable GLP-1 drugs most readers know — semaglutide, tirzepatide, retatrutide — are peptides: chains of amino acids that the gut breaks down, which is why they are injected. Orforglipron is a chemically synthesized small molecule instead. That single design choice is what lets it survive digestion and work as a pill, and it cascades into every practical difference that follows.
How Orforglipron Works
Orforglipron binds and activates the GLP-1 receptor, the same target as the injectable GLP-1 peptides. Activating that receptor drives the effects the class is known for: reduced appetite, slowed gastric emptying, and glucose-dependent insulin release. Where it differs mechanically from the strongest injectables is that it is a mono-agonist — it hits GLP-1 and only GLP-1, rather than adding the GIP or glucagon receptors that the dual and triple agonists layer on.
Its pharmacology supports the once-daily pill format. Published characterizations describe an oral bioavailability of roughly 30–40% and a half-life around 24–38 hours, long enough for once-daily dosing. Because it is a non-peptide, it is expected not to provoke the immune (anti-drug antibody) response that peptide biologics can.
One practical detail sets it apart from earlier oral GLP-1 efforts: trial and label descriptions note it can be taken any time of day, without food or water timing restrictions. That contrasts with oral semaglutide, which requires a fasting window and specific water rules to absorb. In the ACHIEVE-1 diabetes trial, dosing was titrated upward from a low 1 mg starting dose in steps roughly every four weeks — the gradual ramp used across the program to manage tolerability rather than a fixed target dose for any individual.
How It Differs From Injectable GLP-1 Peptides
For readers used to injectable peptides, the meaningful differences are practical, not just chemical:
| Feature |
Orforglipron (oral) |
Injectable GLP-1 peptides |
| Route |
Once-daily oral tablet |
Subcutaneous injection |
| Reconstitution |
None |
Often required for research/compounded vials |
| Food/water timing |
No restriction (any time of day) |
Varies; oral semaglutide needs fasting + water rules |
| Molecule type |
Non-peptide small molecule |
Peptide |
| Cold chain |
Not required |
Typically refrigerated |
| Manufacturing |
Chemically synthesized at pharmaceutical scale |
Peptide synthesis + injectable fill-finish |
The manufacturing line matters more than it looks. Because orforglipron is a small molecule made by chemical synthesis, it sidesteps the peptide-synthesis and injectable fill-finish bottlenecks that constrain how fast injectable GLP-1 supply can scale. That scalability — a pill that can be produced in the volumes oral pharmaceuticals reach — is a large part of why the compound drew the attention it did, independent of its efficacy numbers.
Affiliate disclosure: The Peptide Catalog earns a commission on purchases made through vendor links on this site.
Orforglipron is a prescription pharmaceutical, not a research-catalog compound, so it is not something to buy through peptide vendors. The injectable agonists it gets measured against — retatrutide and tirzepatide — are the compounds covered in our comparison and buying guides, where current pricing and COA-verified vendors live.
What the Trials Reported
ATTAIN-1 (obesity). The pivotal Phase 3 obesity trial (NCT05869903) randomized 3,127 adults over 72 weeks. On the 36 mg dose, ATTAIN-1 reported a 12.4% mean weight reduction — about 27.3 lb — versus 0.9% on placebo. It reported that 59.6% of participants lost at least 10% of body weight and 39.6% lost at least 15% at the top dose (Aronne et al., NEJM 2025).
ACHIEVE-1 (early type 2 diabetes). This 40-week Phase 3 trial (NCT05971940, n=559) measured blood-sugar control alongside weight. From a baseline A1c of 8.0%, ACHIEVE-1 reported an A1c reduction of roughly 1.5–1.6% across the 12 mg and 36 mg doses versus 0.1% on placebo, with about 73–76% of participants reaching an A1c below 7% versus 28% on placebo. The 36 mg dose also reported a 7.9% weight reduction (about 16.0 lb) over the shorter 40-week window (Rosenstock et al., NEJM 2025).
Both readouts describe an effect that is consistent and dose-dependent — larger doses produced larger changes — landing orforglipron firmly in useful-drug territory for weight and glucose, while its ceiling stays below the injectable multi-agonists covered later.
The FDA Approval as Foundayo
The FDA approved orforglipron under the brand name Foundayo on April 1, 2026 for chronic weight management — adults with obesity, or overweight with at least one weight-related condition. It is the milestone the oral-GLP-1 field had been building toward: a small-molecule GLP-1 agonist cleared as a daily pill rather than an injection.
The type 2 diabetes indication is a separate matter. A diabetes application has been filed, but as of this writing it is pending, not approved. The ACHIEVE-1 glucose data above supported that filing; it does not mean orforglipron is approved to treat diabetes today.
Side-Effect Profile
Orforglipron's adverse events are gastrointestinal-dominant, dose-dependent, and concentrated during titration — the same pattern the entire GLP-1 class shows. In ATTAIN-1, the 36 mg dose reported the following rates versus placebo: nausea 33.7% vs 10.4%, vomiting 24.0% vs 3.5%, diarrhea 23.1% vs 9.6%, constipation 25.4% vs 9.3%, and dyspepsia 14.1% vs 5.0%. These are the effects that tend to ease as the body adjusts to a stable dose.
Tolerability shows up in the discontinuation numbers. ATTAIN-1 reported adverse-event discontinuation rising with dose — 5.1%, 7.7%, and 10.3% at the 6 mg, 12 mg, and 36 mg doses respectively, versus 2.6% on placebo. In other words, roughly one in ten participants at the top dose stopped for side effects.
On the organ-safety questions the class gets scrutinized for, the reported picture so far is reassuring but not final. Phase 1–2 data reported no clinically meaningful liver-enzyme signal, and no pancreatitis, retinal, or optic-neuropathy signal has been reported to date. Post-approval pharmacovigilance is ongoing, which is the normal course for any newly approved drug.
Where Orforglipron Lands vs the Injectable Agonists
This is the honest positioning, and it requires a caveat up front: the comparison below is indirect. These figures come from separate trials with different populations and durations — not head-to-head studies — so they indicate a range, not a precise ranking.
Mechanistically, the three compounds sit on a ladder. Orforglipron is an oral GLP-1 mono-agonist. Tirzepatide is an injectable GLP-1/GIP dual agonist. Retatrutide is an injectable GLP-1/GIP/glucagon triple agonist. More receptors have generally meant more weight loss:
- Orforglipron — ATTAIN-1 reported 12.4% at 72 weeks (36 mg).
- Tirzepatide — SURMOUNT-1 reported 20.9–22.5% at 72 weeks (15 mg) (Jastreboff et al., NEJM 2022).
- Retatrutide — its Phase 2 trial reported 24.2% at 48 weeks (12 mg) (Jastreboff et al., NEJM 2023).
On blood sugar the pattern holds: orforglipron's roughly 1.5–1.8% A1c reduction across its trials sits below the roughly 2.3% that injectable tirzepatide reported in its SURPASS-2 diabetes trial. That gap is consistent with single-receptor versus multi-receptor agonism, and it is the expected trade-off of the pill.
So the takeaway is not that orforglipron is weak — a documented 12% weight reduction is a genuine clinical result. It is that orforglipron's advantage is the oral route and manufacturing scale, not peak efficacy. For the readers to whom a daily pill, no needles, and no cold chain matter most, that trade may be the point. For those chasing the largest possible loss, the injectable dual and triple agonists still report higher ceilings.
References
| Citation |
Topic |
| Aronne LJ et al. ATTAIN-1. NEJM 2025;393:1796-1806. NCT05869903 |
Phase 3 obesity: 12.4% weight loss at 36 mg, 72 weeks; ≥10%/≥15% responder rates; AE discontinuation |
| Rosenstock J et al. ACHIEVE-1. NEJM 2025. PMID 40544435. NCT05971940 |
Phase 3 early T2D: A1c 1.5–1.6% reduction, A1c <7% response, 7.9% weight loss at 40 weeks |
| Jastreboff AM et al. SURMOUNT-1. NEJM 2022;387:205-216. PMID 35658024 |
Tirzepatide comparator: 20.9–22.5% weight loss at 72 weeks (15 mg) |
| Jastreboff AM et al. Retatrutide Phase 2. NEJM 2023. PMID 37366315 |
Retatrutide comparator: 24.2% weight loss at 48 weeks (12 mg) |
This article reports on an FDA-approved prescription drug and cross-references investigational and research compounds for context. Nothing here is medical advice or a recommendation to use any compound. Consult a licensed clinician for treatment decisions.